Inventor · disambiguated record
John Marshall
Also filed as: MARSHALL JOHN · MARSHALL JOHN G · MARSHALL JOHN GREOGRY · MARSHALL JOHN L
66 granted patents·68 pending applications·1,496 citations·filing 1993–2025
99Inventor score
Top patents by PatentIndex Score
134 records- 0196US11879020B2Cyclic peptidomimetic for the treatment of neurological disordersUNIV BROWN·Filed 2022·Granted Jan 23, 2024·2 cites·1 claims
- 0296US6890763B2Biopolymer marker indicative of disease state having a molecular weight of 1350 daltonsSYN X PHARMA INC·Filed 2001·Granted May 10, 2005·79 cites·6 claims
- 0396US5948767ACationic amphiphile/DNA complexesGENZYME CORP·Filed 1996·Granted Sep 7, 1999·271 cites·13 claims
- 0494US5783565ACationic amphiphiles containing spermine or spermidine cationic group for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1996·Granted Jul 21, 1998·123 cites·4 claims
- 0594US5719131ACationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1995·Granted Feb 17, 1998·119 cites·24 claims
- 0692US11008316B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2017·Granted May 18, 2021·6 cites·2 claims
- 0792US6071890AOrgan-specific targeting of cationic amphiphile/DNA complexes for gene therapyGENZYME CORP·Filed 1995·Granted Jun 6, 2000·128 cites·14 claims
- 0889US5935936ACompositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1996·Granted Aug 10, 1999·85 cites·20 claims
- 0989US5650096ACationic amphiphiles for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1994·Granted Jul 22, 1997·92 cites·7 claims
- 1088US7329501B2Interalpha trypsin inhibitor biopolymer markers indicative of insulin resistanceNANOGEN INC·Filed 2006·Granted Feb 12, 2008·7 cites·10 claims
- 1186US12060349B2Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2021·Granted Aug 13, 2024·1 cites·7 claims
- 1284US7015004B2Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted Mar 21, 2006·6 cites·9 claims
- 1384US6602855B2Biopolymer marker indicative of disease state having a molecular weight of 1449 daltonsSYN X PHARMA INC·Filed 2001·Granted Aug 5, 2003·26 cites·9 claims
- 1483US6891154B2Amino acid sequence pattern matchingSYN X PHARMA INC·Filed 2002·Granted May 10, 2005·13 cites·16 claims
- 1582US12240920B2Cyclic peptidomimetic for the treatment of neurological disordersUNIV BROWN·Filed 2023·Granted Mar 4, 2025·0 cites·6 claims
- 1682US7179606B2IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's diseaseSYN X PHARMA INC·Filed 2001·Granted Feb 20, 2007·23 cites·9 claims
- 1782US6620786B2Biopolymer marker indicative of disease state having molecular weight of 2937 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·19 cites·9 claims
- 1882US2025026749A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2024·Application pending·0 cites
- 1981US8673857B2Long term potentiation with cyclic-GluR6 analogsMARSHALL JOHN·Filed 2010·Granted Mar 18, 2014·6 cites·6 claims
- 2081US6627606B2Biopolymer marker indicative of disease state having a molecular weight of 1465 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·18 cites·9 claims
- 2181US6617308B2Biopolymer marker indicative of disease state having a molecular weight of 1865 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 9, 2003·18 cites·9 claims
- 2281US5939401ACationic amphiphile compositions for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1996·Granted Aug 17, 1999·37 cites·5 claims
- 2380US5840710ACationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1995·Granted Nov 24, 1998·51 cites·36 claims
- 2479US6677303B2Biopolymer marker indicative of disease state having a molecular weight of 1097 daltonsSYN X PHARMA·Filed 2001·Granted Jan 13, 2004·16 cites·9 claims
- 2579US6620787B2Biopolymer marker indicative of disease state having a molecular weight of 2267 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 16, 2003·16 cites·9 claims
- 2678US6703366B2Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltonsFiled 2001·Granted Mar 9, 2004·15 cites·9 claims
- 2778US5981714AAntibodies specific for cystic fibrosis transmembrane conductance regulator and uses thereforGENZYME CORP·Filed 1996·Granted Nov 9, 1999·53 cites·10 claims
- 2876US11612642B2Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stressBEYOND BARRIERS THERAPEUTICS INC·Filed 2020·Granted Mar 28, 2023·1 cites·17 claims
- 2975US5910487ACationic amphiphiles and plasmids for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1995·Granted Jun 8, 1999·28 cites·7 claims
- 3074US7314717B2Biopolymer marker indicative of disease state having a molecular weight of 1562 daltonsNANOGEN INC·Filed 2001·Granted Jan 1, 2008·10 cites·9 claims
- 3174US6627608B2Biopolymer marker indicative of disease state having a molecular weight of 1206 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·15 cites·9 claims
- 3274US6593298B2Biopolymer marker indicative of disease state having a molecular weight of 1690 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 15, 2003·16 cites·9 claims
- 3374US6383814B1Cationic amphiphiles for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1999·Granted May 7, 2002·32 cites·16 claims
- 3473US7135297B2Protein biopolymer markers indicative of insulin resistanceNANOGEN INC·Filed 2001·Granted Nov 14, 2006·8 cites·9 claims
- 3572US12257292B2Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stressBEYOND BARRIERS THERAPEUTICS INC·Filed 2022·Granted Mar 25, 2025·0 cites·19 claims
- 3672US6756476B2Biopolymer marker indicative of disease state having a molecular weight of 2021 daltonsSYN X PHARMA INC·Filed 2001·Granted Jun 29, 2004·14 cites·9 claims
- 3772US5981275ATransgene expression system for increased persistenceGENZYME CORP·Filed 1997·Granted Nov 9, 1999·27 cites·4 claims
- 3872US2021261557A1Glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2021·Application pending·0 cites
- 3971US6599877B2Biopolymer marker indicative of disease state having a molecular weight of 1020 daltonsSYN X PHARMA INC·Filed 2001·Granted Jul 29, 2003·13 cites·9 claims
- 4071US2021393590A1Inhibitors of glucosylceramide synthaseGENZYME CORP·Filed 2021·Application pending·0 cites
- 4170US10046024B2Cyclic-GluR6 analogs, methods of treatment and useUNIV BROWN·Filed 2016·Granted Aug 14, 2018·1 cites·7 claims
- 4269US9403876B2Cyclic-GluR6 analogs, methods of treatment and useSPALLER MARK·Filed 2010·Granted Aug 2, 2016·3 cites·22 claims
- 4369US7094549B2Fibronectin biopolymer marker indicative of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted Aug 22, 2006·2 cites·9 claims
- 4469US7052849B2Protein biopolymer markers predictive of insulin resistanceSYN X PHARMA INC·Filed 2001·Granted May 30, 2006·7 cites·9 claims
- 4569US6627607B2Biopolymer marker indicative of disease state having a molecular weight of 1845 daltonsSYN X PHARMA INC·Filed 2001·Granted Sep 30, 2003·12 cites·9 claims
- 4669US5747471ACationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic moleculesGENZYME CORP·Filed 1995·Granted May 5, 1998·37 cites·20 claims
- 4769US2021369672A1Inhibitors of glucosylceramide synthaseGENZYME CORP·Filed 2021·Application pending·0 cites
- 4868US2024002783A1Method for stimulating the growth of a cell1000414206 ONTARIO INC·Filed 2023·Application pending·0 cites
- 4967US7294688B2Biopolymer marker indicative of disease state having a molecular weight of 1348 daltonsNANOGEN INC·Filed 2001·Granted Nov 13, 2007·5 cites·1 claims
- 5066US7074576B2Protein biopolymer markers indicative of alzheimer's diseaseSYN X PHARMA INC·Filed 2001·Granted Jul 11, 2006·1 cites·9 claims
Showing the top 50 of 134 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John Marshall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →